CG Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CGON research report →
Range $80 – $100
Price Chart
About the company
CG Oncology, Inc. , a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
- CEO
- Arthur Kuan
- IPO
- 2024
- Employees
- 142
- HQ
- Dallas, TX, US
Get TickerSpark's AI analysis on CGON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.77B
- P/E
- -24.35
- Fwd P/E
- 24.59
- PEG
- 0.64
- P/S
- 930.99
- P/B
- 5.63
- EV/EBITDA
- -26.04
- Div Yield
- 0.00%
- Gross Margin
- -82.69%
- Op Margin
- -4056.18%
- Net Margin
- -3602.68%
- ROE
- -25.20%
- ROIC
- -24.30%
Latest fiscal year · YoY change
- Revenue
- $4.04M+254.7%
- Gross Profit
- $-607,000+99.3%
- Op Income
- $-190,774,000
- Net Income
- $-160,995,000-82.9%
- EPS
- $-2.08-47.5%
- OCF Growth
- -68.1%
- FCF Growth
- -67.8%
- 52W High
- $80.97
- 52W Low
- $35.80
- 50D MA
- $73.98
- 200D MA
- $64.06
- Beta
- 0.24
- RSI (14)
- 36
- Avg Volume
- 902.31K
No earnings-call transcripts are available for CGON yet.
- Free Float
- 74.6%
- Shares Outstanding
- 88.20M
- Float Shares
- 65.82M
of shares held by institutions
246 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 8.51M | ▲ 1.53M |
| T. Rowe Price Investment Management, Inc. | 6.62M | ▼ 103.49K |
| Vanguard Group Inc | 6.54M | ▼ 37.80K |
| Decheng Capital LLC | 6.37M | 0 |
| Blackrock, Inc. | 6.26M | ▲ 1.19M |
| Wellington Management Group Llp | 5.32M | ▼ 46.48K |
| Fmr LLC | 4.16M | ▲ 396.65K |
| Price T Rowe Associates Inc | 3.81M | ▲ 152.03K |
| Tcg Crossover Management, LLC | 3.67M | 0 |
| Vanguard Portfolio Management LLC | 3.47M | ▲ 370.10K |
| State Street Corp | 3.44M | ▲ 790.54K |
| Vanguard Capital Management LLC | 3.32M | ▲ 283.17K |
Held by 348 ETFs
Biggest fund positions in CGON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | POST LEONARD E | other | 1,000 |
| Sep 15, 26 | POST LEONARD E | other | 1,000 |
| Sep 15, 26 | POST LEONARD E | sell | 1,000 |
| Aug 14, 26 | POST LEONARD E | other | 1,000 |
| Aug 14, 26 | POST LEONARD E | other | 1,000 |
| Aug 14, 26 | POST LEONARD E | sell | 1,000 |
| Jul 15, 26 | POST LEONARD E | other | 1,000 |
| Jul 15, 26 | POST LEONARD E | other | 1,000 |
| Jul 15, 26 | POST LEONARD E | sell | 1,000 |
| Jul 10, 26 | Mulay James | other | 24,165 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CGON coverage
Recent articles, reports, and earnings notes.
No research on CGON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CGON report →Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in Stock
defenseworld.net · Sep 20
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC
defenseworld.net · Sep 5
15 Stocks to Watch With Short Squeeze Potential
schaeffersresearch.com · Sep 2
CG Oncology to Present at Upcoming Investor Conferences in September
globenewswire.com · Sep 2
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
prnewswire.com · Aug 19
CG Oncology: Circling Back After Huge Rally
seekingalpha.com · Aug 13
CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System
defenseworld.net · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.